Benitec Biopharma (BNTC) vs Galectin Therapeutics (GALT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Benitec Biopharma (BNTC) has outperformed Galectin Therapeutics (GALT) over the past year, losing 40.3% versus a loss of 49.7%. Over five years, GALT leads with a +4.7% price change compared with -85.7% for BNTC. Benitec Biopharma is the larger company by market cap ($285.9 million vs $271.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BNTC | GALT |
|---|---|---|
| Share price | $7.92 | $2.69 |
| Market cap | $285.88M | $271.35M |
| 1-day change | -2.76% | -4.27% |
| YTD return | -41.24% | -35.34% |
| 1-year return | -40.31% | -49.72% |
| 5-year return | -85.67% | +4.67% |
| EPS (TTM) | $-1.02 | $-0.32 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-45.55M | $-30.84M |
| 52-week high | $14.39 | $7.13 |
| 52-week low | $7.72 | $2.03 |
| Distance from 52-week high | -45.00% | -62.27% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +200.06% | +308.92% |
| Average volume | 174.01K | 252.31K |
| Shares outstanding | 36.12M | 100.88M |
| Employees | 24 | 9 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Benitec Biopharma
BNTC stock →Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines in the United States. Its Silence and Replace, a DNA-directedRNA interference platform, that combines RNA interference with gene therapy to create medicines which simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct.
Health Care · Biotechnology: Pharmaceutical Preparations · 24 employees
About Galectin Therapeutics
GALT stock →Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
BNTC vs GALT FAQ
Which is bigger, Benitec Biopharma or Galectin Therapeutics?
Benitec Biopharma (BNTC) is larger, with a market capitalization of $285.88M compared with $271.35M for Galectin Therapeutics (GALT).
Which stock has performed better over the past year, BNTC or GALT?
BNTC returned -40.31% over the past 12 months, compared with -49.72% for GALT (price return, excluding dividends). Past performance does not predict future results.
Are Benitec Biopharma and Galectin Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.